Title: Metabonomic and Microbiological Analysis of the Dynamic Effect of Vancomycin-Induced Gut Microbiota Modification in the Mouse

Author lists: Ivan K. S. Yap,[†*] Jia V. Li,[†*] Jasmina Saric,[†,‡] Francois-Pierre Martin,[Δ] Huw Davies,[†] Yulan Wang,[†] Ian D. Wilson,[§] Jeremy K. Nicholson,[†] Jürg Utzinger,[‡] Julian R. Marchesi,[¥#] Elaine Holmes[†]

†Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, UK; ‡Department of Public Health and Epidemiology, Swiss Tropical Institute, P.O. Box, CH-4002 Basel, Switzerland; ΔNestlé Research Center, P.O. Box 44, Vers-chez-les-Blanc, CH-1000 Lausanne 26, Switzerland; §Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Mereside, Macclesfield, Cheshire SK10 4TG, UK; ¥Alimentary Pharmabiotic Centre and Department of Microbiology, University College Cork, Western Road, Cork, Ireland; #School of Biosciences, Cardiff University, Cardiff CF10 3TL, Wales, UK.
* contribute equally in this work.

Correspondence should be addressed to Prof. E. Holmes (elaine.holmes@imperial.ac.uk) Tel: +44 (0)20 7594 3220

Abbreviations: COSY, ^{1}H-^{1}H correlation spectroscopy; FID, free induction decay; IBS, irritable bowel syndrome; NMR, nuclear magnetic resonance; O-PLS-DA, orthogonal signal correction-projection to latent structure-discriminant analysis; PCR-

DGGE, polymerase chain reaction-denaturing gradient gel electrophoresis; RD, recycle delay; SCFA, short chain fatty acid; STOCSY, statistical total correlation spectroscopy; TMA, trimethylamine; TMAO, trimethylamine-*N*-oxide; TOCSY, ^{1}H-^{1}H total correlation spectroscopy; TSP, 3-trimethylsilyl-1-[2,2,3,3-^{2}H4] propionate

Abstract

The effects of the antibiotics vancomycin (2 x 100 mg/kg/day) on the gut microbiota of female mice (outbred NMRI strain) were studied, in order to assess the relative contribution of the gut microbiome to host metabolism. The host's metabolic phenotype was characterized using ^{1}H NMR spectroscopy of urine and fecal extract samples. Time-course changes in the gut microbiotal community after administration of vancomycin were monitored using 16S rRNA gene PCR and denaturing gradient gel electrophoresis (PCR-DGGE) analysis and showed a strong effect on several species, mostly within the Firmicutes. Vancomycin treatment was associated with fecal excretion of uracil, amino acids and short chain fatty acids (SCFAs), highlighting the contribution of the gut microbiota to the production and metabolism of these dietary compounds. Clear differences in gut microbial communities between control and antibiotic-treated mice were observed in the current study. Reduced urinary excretion of gut microbial co-metabolites phenylacetylglycine and hippurate was also observed. Regression of hippurate and phenylacetylglycine concentrations against the fecal metabolite profile showed a strong association between these urinary metabolites and a wide range of fecal metabolites, including amino acids and SCFAs. Fecal choline was inversely correlated with urinary hippurate. Metabolic profiling, coupled with the metagenomic study of this antibiotic model, illustrates the close inter-relationship between the host and microbial "metabotypes", and will provide a basis for further experiments probing the understanding of the microbial-mammalian metabolic axis.

INTRODUCTION

The mammalian gut contains hundreds of species of commensal and symbiotic microbes, which mainly reside in the large intestine, and the caecum for rodents, where they contribute to ~60% of the total fecal mass produced.[1,2] It is widely acknowledged that the presence of the gut microbiota is a key factor in gut development, structure and function.[3-5] Intestinal microbiota may also play a major role in the etiology of many gut disorders, such as irritable bowel disease (IBD) and colon cancer.[6,7] Moreover, the microbiome has recently been reported to vary significantly between obese individuals (human and animals) and normal individuals, and it is known to provide refined control mechanisms on energy recovery through catabolism of otherwise poorly digestible nutrients, i.e., resistant starch and other polysaccharides.[8-10] Since the microbiota are extremely metabolically active and co-metabolize many endogenous and xenobiotic compounds, they clearly have the potential to affect the biochemical composition of the tissues and biofluids of the host.[11,12]

Previous research revealed the influence of the gut microbiota on the urinary metabolite composition in rodent studies using metabolic profiling methods based on ^{1}H nuclear magnetic resonance (NMR) spectroscopy.[11-17] In particular, diet, medication and environmental-induced effects on aromatic components such as hippurate and 3-hydroxyphenylpropionic acid (HPPA), which are known to be generated or co-metabolized by gut microbiota, are well documented in conjunction with a variety of other metabolic pathways such as those involved with bile acid catabolism, choline metabolism and utilization of short chain fatty acids (SCFAs).[11-17] Further evidence of the direct contribution of the microbiota to host metabolism has

been obtained using metabolic profiling methods to characterize germ-free and antibiotic-rodent models.[12,13,18,19]

Although germ-free models provide valuable information on microbial-mammalian co-metabolism, acting in some respects as a "knock out", it could be argued that, since the gut of such animals remains underdeveloped, they do not offer a true picture of 'normal' mammalian physiology and as such are not an optimal model for characterizing microbiota-mammalian metabolic interaction in 'normal' animals. An alternative approach is to employ conventional animals, with normal gut physiology, combined with antimicrobial treatment, which mimics more closely the actual environment of the host gut and its commensals. Indeed, from studies aimed at the deliberate reduction of the gut microbiota, as well as on the investigation of antibiotic-induced nephrotoxicity of pharmacological effects on the gut microbiota, a reduction in the urinary excretion of hippurate and other phenolic metabolites was evident.[13,20,21]

As part of ongoing studies to determine the effect of the gut microbiota on host metabolic phenotypes, we employ here an antibiotic-based model to directly probe the dynamic effect of the microbiotal contribution to urinary and fecal composition. Additionally, we monitor time-course changes in the gut microbiota community during the course of the recovery using 16S rRNA gene polymerase chain reaction (PCR) and denaturing gradient gel electrophoresis (DGGE) analysis. For this, we have used vancomycin (a glycopeptide antibiotic,[22] with broad activity against Gram-positive bacteria), which causes marked decrease in gut microbiotal populations in mice.[23] Vancomycin was chosen as a means of reducing the Gram-positive bacteria in the gut without overtly modifying the Gram-negative microbes, in order to target one particular aspect of the microbial influence on host metabolism. Additionally,

vancomycin is known to be poorly partitioned across the mammalian gastrointestinal mucosa and since it does not have systemic absorption, should not perturb host biochemistry directly.[23]

METHODS

Two studies were initiated to assess effects of antibiotic treatments on host-gut metabolism. The initial exploratory study was used to monitor metabolic changes in the mouse at a single time point. A second study, hereafter referred to as the extension study, was carried out to ascertain the dynamic metabolic effects of antibiotic treatments in mice.

Exploratory Study Design. This study was carried out at the animal care facilities of the Swiss Tropical Institute (Basel, Switzerland), and complied with Swiss local and national regulations on animal welfare (permission no. 2081). Twelve female (age: ~3 weeks; weight: 20-25 g) outbred NMRI strain mice were purchased from RCC (Füllinsdorf, Switzerland). The animals were kept in groups of 3 in macrolon^{TM} cages, and acclimatized for 7 days prior to the study under controlled environmental conditions (temperature: ~22ºC; relative humidity: ~70%; day/night cycle: 12-12 h). Mice were fed commercial rodent feed with water *ad libitum*. Six of the mice were dosed with vancomycin hydrochloride (2 x 100 mg/kg/day) on day 25 of the study for 2 successive days. Mice were treated orally by gastric intubation with vancomycin suspended in 7% Tween-80 and 3% ethanol (volume 10 ml/kg body weight; serving as vehicle). The remaining six mice were given the vehicle only (10 ml/kg body weight), and hence served as controls.

Fecal and urine sample collection was carried out 2 days after the initial dosing (i.e., day 27) between 09.00 and 11.00 hours. From each mouse, urine (at least 20 µl) and fecal samples (1-2 pellets) were collected into Petri dishes by gently stretching the mice or rubbing their abdomen. Samples were transferred into small microcentrifuge tubes, immediately frozen over dry ice and stored at -80ºC.

Extension Time-Course Study Design. A total of 20 NMRI female mice were purchased from RCC and divided into the control and vancomycin-treated groups with 10 mice each. Each mouse from the vancomycin treatment group was treated in the same way as the first study at 15-week-old, while mice from control group were administered 3 doses of drug vehicle only (age: 14 weeks). The 1-week difference in the age at the start of the experiment between this and the exploratory study can be ignored since mice are fully mature at this age and thus their microbial community would be fully established. Urine and stool samples for NMR experiments were collected from both groups at 1 day pre-dosing and days 1, 2, 3, 5, 7, 13, 19 after the final dosing and stored at -40°C. Stool samples for microbiological investigation were also collected at the same time points, fixed in 0.5 ml of 4% formalin, to which 9.5 ml of 70% (v:v) ethanol was added and stored at -20°C.

Sample Preparation. Urine samples were prepared by mixing 20 µl of urine with 30 µl of a phosphate buffer containing 90% D_2O and 0.25 mM 3-trimethylsilyl-1-[2,2,3,3-²H4] propionate (TSP) and left to stand for 10 min. The resulting mixtures were then transferred into 1.7 mm (outer diameter) NMR capillary tubes.

Each fecal sample was homogenized with buffer (1 ml, 0.2 M sodium phosphate, pH 7.4). Homogenates were sonicated at ambient temperature (25°C) for 30 min and centrifuged at 11000 g for 10 min. The supernatants (460 µl) were aliquoted and a final volume of 700 µl was made by the addition of 240 µl of TSP in 90% D_2O. These were further centrifuged at 11000 g for 10 min and 600 µl of the supernatant was pipetted into 5 mm NMR tubes.

¹H NMR Spectroscopy. Spectra were obtained on a Bruker DRX600 spectrometer (Bruker Biospin; Rheinstetten, Germany) at 600.13 MHz (ambient probe temperature 27°C). A standard 1-dimensional (1D) pulse sequence was used [recycle delay (RD)-90°-t_1-90°-t_m-90°-acquire free induction decay (FID)]. The water signal was suppressed by irradiation during RD of 2 s, and mixing time (t_m) of 150 ms. t_1 was set to 3 μs and the 90° pulse length was adjusted to ~10 μs. For each sample, a total of 64 transients (in exploratory study) and 256 transients (in the extension study) were accumulated into ~32,000 data points using a spectral width of 20 ppm. Prior to Fourier transformation, all FIDs were multiplied by an exponential function equivalent to a line broadening of 0.3 Hz. The assignment of the peaks to specific metabolites was based on 2-dimensional (2D) ¹H-¹H correlation spectroscopy (COSY) and ¹H-¹H total correlation spectroscopy (TOCSY) NMR, published literature,[24,25] and statistical total correlation spectroscopy (STOCSY).[26]

Data Processing and Analysis. ¹H NMR spectra of fecal extract and urine samples were manually phased and baseline corrected using XwinNMR 3.5 (Bruker Biospin; Rheinstetten, Germany). The ¹H NMR spectra were referenced to the TSP resonance at δ 0.0. The spectra were digitized using a MATLAB (version 7, The Mathworks Inc.; Natwick, MA, USA) script developed in-house. The region containing the water resonance was removed from each spectrum to eliminate baseline effects of imperfect water saturation. For each spectrum, normalization to the total sum of the residual spectrum was carried out on the data prior to pattern recognition analyses followed by scaling of the data to unit variance.

Principal component analysis (PCA) was applied to the processed spectral data to reveal intrinsic treatment-related patterns within data as well as monitoring

the dynamic response of the mice to vancomycin intervention. Inter-animal variation can confound data interpretation, particularly in multivariate data of high dimensionality. Therefore, orthogonal-projection to latent structure discriminant analysis (O-PLS-DA)[27] was performed in a MATLAB environment to optimally model class differences and to systematically identify metabolites contributing to the differences between the vancomycin-treated and control groups. The O-PLS-DA method decomposes the variation in X (NMR data) into 3 parts; the first being the variation in X related to Y (the class variable), and the last 2 containing the specific systemic variation in X and residual, respectively. The contribution of each metabolite to sample classification is interpreted using the O-PLS coefficients with back-scaling transformation, indicating the variable contributions to the antibiotic-induced discrimination in the models.[28] Here, the colors projected onto the spectrum indicate the correlation of the metabolites discriminating vancomycin-treated mice from the corresponding controls. Red indicates a high correlation and blue denotes no correlation with sample class. The direction and magnitude of the signals relate to the covariation of the metabolites with the classes in the model. A coefficient of 0.71, corresponding to a 95% significance level, was used as a cut-off value to select variables that had a significant correlation with class and the model predictive performance (robustness) was evaluated using a 7-fold cross validation method.[28]

Two of the 3 urinary metabolites that were most highly correlated with antibiotic ingestion, namely hippurate and phenylacetylglycine, were regressed against the total fecal metabolite profiles using O-PLS analysis based on the integrated hippurate resonance at δ 7.84, or the integrated phenylacetylglycine resonance at δ 7.43, as the Y or response matrix. The third metabolite,

guanidinoacetate, was not integrated due to substantial peak overlap, which would lead to inaccuracy in the calculation.

Microbiological Analysis (PCR-DGGE Experiment). DNA Extraction. Approximately 0.2 g of stool sample was processed to remove preservation solution (2 washes with 0.5 ml PBS) and mixed with 1.4 ml of buffer ASL, the suspension was transferred into a plastic tube containing 1 g of 0.1 mm diameter zirconium/glass beads and vortexed for 1 min at maximum speed to ensure the sample was thoroughly homogenized. The DNA extraction was carried out using QIAamp DNA Stool Mini Kit (Qiagen, Dublin, Ireland) according to the manufacturer's instructions. The 16S rRNA gene was amplified using a nested approach, the first PCR used primers 27f (5' GAGTTTGATCMTGGCTCAG 3') and 1492r (5' GGYTACCTTGTTACGACTT 3') and the second PCR was performed with 341fGC primers (5' CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGTACG-GGAGGCAGCAG 3') and 519r primers (5' GTATTACCGCGGCTGGCTG 3'). DGGE analysis was performed as described elsewhere.[30] A number of strong discriminatory DGGE bands were excised with a sterile pipette tip into sterile water, amplified and cleaned (QIAquick PCR Purification Kit, Qiagen, Dublin, Ireland) for the sequencing. The amplicon was purified (QIAquick PCR Purification Kit, Dublin, Ireland) and sequenced by GATC (Konstanz, Germany), phylogenetic analysis was performed using the RDP classifier tool.[31] Additional PCR was performed using specific primers (*Clostridium leptum* sub-group or the *C. coccoides* sub-group) based on the extracted DNA and the PCR products were visualized on agarose gels by staining with ethidium bromide. [31]

RESULTS

Data obtained from both the exploratory and extension studies revealed consistent changes in the urinary and fecal metabolic profiles with the time course study generating further information on recovery of individual metabolites and the global profile after antibiotic intervention. The control and treated groups excreted drug vehicle (7% Tween / 3% ethanol) in their feces on day 1 but was eliminated within 48 hours. No significant endogenous changes in metabolite profile were observed in the first 3 PCs.

Vancomycin-Induced Effects on the ^{1}H NMR Spectroscopic Profiles of Urine Samples. Typical examples of the ^{1}H NMR spectra of urine obtained from an untreated and a vancomycin-treated mouse are shown in Figures 1A and 1B. Spectra from control mice were dominated by a number of metabolites, namely α-ketoglutarate, α-ketoisocaproate, α-ketoisovalerate, *n*-butyrate, citrate, creatine, creatinine, dimethylamine, fumarate, glycine, hippurate, lactate, *N*-acetyl glycoprotein fragments, phenylacetylglycine, succinate, taurine, trimethylamine, and trimethylamine-*N*-oxide. Visual inspection of the spectra revealed marked differences in overall metabolic composition between urines obtained from untreated and vancomycin-treated mice, with the latter showing relatively lower concentrations of urinary phenylacetylglycine, hippurate and fumarate, and higher levels of urinary creatine, α-ketoisocaproate and α-ketoisovalerate. To examine the metabolic disturbance resulted from vancomycin in urine over all the time points, a PCA strategy was applied to the entire data set. A total of 3 principal components (PCs) were calculated for a PCA model using unit variance scaled spectral data shown in Figure 1C. There was clear separation between urine samples obtained from control

mice and mice given vancomycin 1-3 days after the final dosing. At days 5 and 7 post-treatment, samples from treated mice were still differentiated but moved closer to the control cluster, finally co-mapping with the control cluster by day 13 post-treatment.

In addition to visually identified metabolites, O-PLS-DA (Figure 2) highlighted further discriminatory metabolites for the antibiotic-treated group, with vancomycin-treated mice showing lower levels of urinary trimethylamine and trimethylamine-*N*-oxide, and the higher levels of urinary *n*-butyrate, guanidinoacetic acid and *N*-acetyl glycoprotein fragments. However, Student's *t*-tests of the urinary NMR data revealed that only guanidinoacetic acid and hippurate showed statistical significance at a 95% confidence interval. The model parameters for urine samples are given in Table 1 together with the O-PLS-DA correlation coefficients indicating the relative contributions of key metabolites contributing to the antibiotic-perturbed profiles.

In urinary O-PLS-DA plots comparing control and treated animals for each of the 7 time points, 3 dominant metabolites i.e., hippurate, phenalactyglycine (PAG) and creatine, were found to co-vary consistently during the course of the recovery from vancomycin treatment. The mean integrated signals for these metabolites relative to the total spectrum were calculated and plotted (Figure 2B). Urinary concentrations of both hippurate and PAG decreased after the vancomycin treatment. However, the "recovery" of hippurate towards control levels was slower (*ca* 19 days) than that of PAG (*ca* 7 days). Urinary creatine was increased at days 1 and 2 post-vancomycin treatment and recovered from day 3 onwards.

Vancomycin-Induced Effects on the Fecal Metabolite Profiles. Typical examples of the ^{1}H NMR spectra of fecal extracts obtained from an untreated and a

vancomycin-treated mouse are shown in Figures 3A and 3B. A range of metabolites such as amino acids, SCFAs, uracil and succinate were also directly assigned in spectra from control and vancomycin-treated mice consistent with previously published data.[16,17,24,25] Reduction in the relative concentrations of fecal amino acids, SCFAs and uracil, and an increase in fecal choline and oligosaccharide levels were observed in vancomycin-treated mice. The PCA plot of fecal samples collected over the entire study duration (Figure 3C) showed a similar metabolic movement to that observed for the urinary data. At days 1 and 3 post-vancomycin dosing, the fecal water composition was markedly different from that of controls. In terms of the number of perturbed metabolites, vancomycin showed a greater effect in faecal water than in urine.

Systematic comparison of the treated and control groups using O-PLS generated strong models with goodness of fit, R^2, of 98.3% and goodness of prediction,[27,28] Q^2, of 92.3%, and showed good discrimination in the scores plot (Figure 2), indicating that vancomycin caused a substantial and significant effect on the fecal composition as compared to the urinary changes. The O-PLS coefficients plot (Figure 4) confirmed the observed metabolic changes and also identified decreased levels of fecal lactate and succinate as significant discriminators of vancomycin treatment. The model parameters for fecal samples are given in Table 2, together with the O-PLS-DA correlation coefficients indicating the relative contributions of key metabolites contributing to the antibiotic-perturbed profiles.

The O-PLS-DA coefficient plot derived from spectra data of fecal water at day 1 post-treatment (data not shown) showed a marked depletion of a range of amino acids including leucine, isoleucine, valine, lysine, glutamate, methionine, taurine and aromatic amino acids such as tyrosine, phenylalanine and cytosine, and SCFAs

(acetate, butyrate), together with other metabolites, such as 5-aminovalerate, succinate, nicotinurate and glucose. Moreover, increased concentrations of choline, oligossacharides and fumarate were also observed in the vancomycin-treated mice. All metabolites showed similar trend of changes during the course of treatment except 5-aminovalerate, which fluctuated and recovered back to "normal" level at day 7 post-treatment. The relative concentrations of selected metabolites were calculated based on the integration of peaks, shown in Figure 4B.

O-PLS Correlation of Urinary Hippurate and Phenylacetylglycine Concentrations with Fecal Metabolites. O-PLS regression of urinary hippurate against the fecal extract profiles (Figure 5A) generated a strong model (R^2=92.9%, Q^2=67.8% using a 1-component model with 1 orthogonal component). Several fecal amino acids were highly correlated with urinary hippurate concentrations, whilst SCFAs (propionate, *n*-butyrate and acetate) and uracil were also significantly positively correlated with urinary hippurate, albeit to a lesser extent. Conversely fecal choline and sugars were inversely correlated with urinary hippurate. Lactate and succinate were uncorrelated with hippurate. The regression model for urinary phenylacetylglycine (Figure 5B) showed correlations with the same molecules as hippurate but the model and correlation coefficients were weaker (R^2=86.2%, Q^2=41.1% using a 1-component model with 1 orthogonal component). Subsequent O-PLS regression analyses were carried out on all the time points (day 1-day 19) and the characteristics of these models are summarized in Table 3. The pattern of changes observed in these models were consistent, with decreasing Q^2 at later time points, indicating weaker correlations between the fecal metabolic profiles and urinary hippurate and phenylacetylglycine concentrations. These findings are

consistent with the changes observed in the quantified urinary metabolites (Figure 2B).

Microbial Diversity with Time and Trajectory of DGGE Data. 16S rRNA PCR-DGGE and sequencing, as a routine molecular approach, was applied to examine disturbance of the microbiota caused by vancomycin treatment in mice over the duration of the extension study time course (19 days). Sequences closely related to *C. leptum*, *C. coccoides*, *C. symbiosum* and *Photorhabdus luminescens* were found to be impacted and were lost from the DGGE profiles 1 day post-treatment (Table 4). However, bands which were shown to be closely related to *C. leptum* and *C. coccoides* recovered at day 2 or day 3 post-treatment.

DISCUSSION

Antibiotics alter the composition of the gut microbiota[32] and play a central role in the development of *C. difficile*-associated colitis.[33] Moreover the gut microbiota is resilient and once the antibiotic source has been removed, it is thought to substantially recover to its original composition and diversity.[32] However, no work to date has shown how a major perturbation of the gut microbiota manifests itself in the host's systemic metabolic phenotype, which is known to be partially under microbiome control.[34] Metabolites synthesized *via* microbiome activity influence host biology and any dysbiosis in this virtual organ has implications for the host health. We undertook to correlate changes in the gut microbiota, induced by exposure to vancomycin, with the host's metabonome[35] and determine to what extent they are associated.

Results obtained from the exploratory and extension studies revealed consistent changes in the urine and fecal metabolic profiles of mice after vancomycin treatment indicating that the vancomycin-induced effect on the microbiotal community was robust and reproducible. In the extension study, we demonstrated recovery from vancomycin treatment with individual metabolites showing differential recovery rates. We also showed clear differences in gut microbial communities between control and antibiotic-treated mice using PCR-DGGE-based microbiological methods. Since all animals were fed with the same food, kept in the same environment and given drug vehicle, it was unlikely that metabolic variation observed were due to environmental conditions. Vancomycin or its metabolites were not detected in any of the urine samples. This was expected since vancomycin does not cross through the intestinal lining; and since feces are excreted within 24 hours after treatment. However, drug vehicle was detected on day 1 from both groups and was eliminated within 48 hours.

Certain drug vehicles have been shown to effect urinary biochemical profiles. However, in a study conducted by Beckwith-Hall *et al.* (2002) Tween exerted the smallest effect on the metabolic profiles after saline consistent with the present study.[36] The spectral regions affected by the vehicle were removed from the data set prior to mathematical modelling to minimise its effect on data analyses and interpretation of the metabolic data.

Previous studies have highlighted the reduction in the urinary excretion of hippurate in both germ-free animals[12] and in rats treated with antibiotics.[13] After exposure to a standard laboratory environment, a dynamic series of changes in the biochemical composition of the urine was observed in germ-free animals, as reflected by sequential excretion of phenylacetylglycine, 4-hydroxyphenylpropionic acid, 3-hydroxyphenylpropionic acid and, finally, hippurate at around 21 days post-exposure. Hippurate is a well described mammalian-microbial co-metabolite[17,37] formed by glycine conjugation of benzoate (predominantly in the liver), which is produced from bacterial metabolism of plant phenols,[38] or by intestinal microbiota in the presence of quinic acid (1,3,4,5-tetrahydroxycyclohexanecarboxylic acid).[39] Depletion of hippurate has been previously reported after ingestion of antibiotics such as cephaloridine,[19,20] gentamicin,[21] neomycin, tetracycline hydrochloride and bacitracin mixture.[13] Gut microbiota also extensively catabolize protein and aromatic amino acids, including phenylalanine, tyrosine and tryptophan.[40] Fecal amino acids, including tyrosine and phenylalanine, were noted to be directly correlated with urinary hippurate and phenylacetylglycine, consistent with decreased catabolism of these amino acids by the microbiota. In the current study vancomycin had a strong impact on the region of the spectrum representing phenolic molecules with particular effect on reduction of signals from hippurate and phenylacetylglycine. Both PAG and hippurate were

observed to be decreased after administration of vancomycin; however, urinary concentrations of PAG were restored to those of controls at day 5, while recovery of urinary hippurate was not experienced until the end of the experiment at day 19 post-treatment. This suggests that establishment of a stable gut microbiota requires a similar time frame in both conventionalisation of germ-free rats and in conventional mice after vancomycin treatment. Such a 19-day recovery of hippurate may reflect a delayed re-population of hippurate-producing microbiota compared with other microbiota.

Other urinary indicators of vancomycin-perturbed microbiota included relative decrease in the concentrations of trimethylamine (TMA), a gut bacterial product of the choline metabolism, and trimethylamine-*N*-oxide (TMAO), a product of its hepatic detoxification.[41,42] Choline metabolism is a complex host-symbiont molecular interaction which involve both mammalian and symxenobiotic (metabolite with dietary and/or gut microbiota origin) metabolic pathways.[16] Although vancomycin treatment did not significantly alter the choline and methylamine content of fecal extracts, a trend towards decreased level of choline in fecal water from vancomycin-treated mice was observed at day 1 post-dosing. The variations of TMA and choline were not observed from day 3 onwards. This might indicate that choline metabolism is influenced by both vancomycin and non-vancomycin sensitive bacteria. In addition, methylamines are known to be co-metabolized by the host and the gut microbiota in the large intestine.[42]

Bacterial fermentation of carbohydrates in the caecum and the large intestine leads to the production of SCFAs and lactic acid depending on the bacterial strains involved.[43-46] We observed lower amounts of fecal acetate, *n*-butyrate, propionate and lactate, and increased quantities of fecal oligosaccharides in mice treated with

vancomycin compared to controls (Table 1), suggesting disruption in carbohydrate fermentation due to vancomycin-induced changes in gut microbial populations. Our observations are consistent with previous *in vitro* experiments using porcine caecal contents to create an *in vitro* model of gut microbial metabolism which showed marked decrease of fecal SCFAs following vancomycin intervention.[47] In particular, fermentation of carbohydrates by the *Bifidobacteria* normally induces a decrease in the pH of the caecal content associated quantitatively with different SCFA profiles of treated animals as compared to control animals, which inhibits the growth of pathogens.[45,48] The disruption of the microbial production of SCFAs after vancomycin administration might thus be expected to profoundly disturb the gut microbial environment and alter relative amounts, and composition of colonic bacterial species.[48] Given that, most of the SCFAs are rapidly absorbed in the ascending part of the colon and represent potential substrates for the liver and various tissues such antibiotic-induced effects might have significant nutritional consequences for the host.[45,49,50] The disruption of the SCFA bacterial metabolism results in a loss of bioavailability of these metabolites for the host metabolism, possibly related to the observed reduction in urinary elimination of n-butyrate and α-ketoisovalerate (Table 2). In addition, the reduction in n-butyrate production might have physiological consequences for individual animals because bacterial n-butyrate has a 'trophic' effect on colonocytes.[2,45] Previous studies have shown the contribution of gut microbiota to mammalian host metabolism by measuring specific groups of compounds such as amino acids, bile acids, SCFAs, monitoring changes in fecal ammonia and host physiological descriptors such as those related to energy expenditure, lipoprotein profile and recovery from gut dysbiosis.[51-53] Interestingly, fecal lactate did not correlate with urinary hippurate (Figure 5a) and may reflect the

fact that urinary lactate contains both the D- and L-enantiomers, of mixed host and microbial sources whereas fecal lactate is predominantly produce by bacteria and therefore is mainly in the D- form.

Another prominent finding is the reduction in the concentrations of SCFAs including acetate and butyrate, together with increased concentrations of oligosaccharides in faecal water from vancomycin-treated mice compared with that from control mice on days 1, 3, 5 and 7. This is consistent with a previous study where Bender *et al.* (2001) employed an *in vitro* model for the semi-continuous incubation of defined colon contents to examine the effect of vancomycin on SCFAs composition.[47] These SCFAs are derived from the fermentation of non-gastric-digestible starches and oligosaccharides by saccharolytic bacteria. The composition of fermentation end-products is dependent on the bacteria species, substrates and chemical environment, such as pH.[48] Rycroft *et al.* (2001) reported that galacto-oligosaccharides generated high levels of SCFAs and decreased the numbers of clostridia.[54] Among these SCFAs, *n*-butyrate seems to be most beneficial to colon cellular functions, such as proliferation, membrane synthesis and sodium absorption growth, and it also shows effect of anti-colon carcinogenesis and anti-tumour activity.[55,56] In the present study, the 'abnormal' levels of SCFAs, which lasted for 13 days, indicated a large amount of microbiota experienced reduced activities, unlike *C. coccoides* and *C. leptum* which recovered from day 2 onwards. Interestingly, there was an increase in species diversity in the vancomycin-treated group supported by the increased number of DNA bands appearing on the DGGE gels. Although those species could not be unequivocally identified here, this gross observation is in agreement with a previous human study,[53] which reported a marked elevation in total numbers of *Clostridium* bacteria including *C. bifermentans, C. clostridioforme,*

C. sordellii and *C. malenominatum*, and an increased species diversity in the elderly people under antibiotic treatment.

In the current study lower fecal concentration of amino acid levels were observed in vancomycin-treated mice (Table 1, Figure 4), which may affect the complex fluxes of amino acids and protein nitrogen across the intestinal mucosa.[57] Although gastrointestinal digestion of some dietary proteins is incomplete, only about 2-5% escapes small intestinal digestion/absorption. Immense populations of bacteria living within the large intestine are key contributors to the digestion and metabolism of amino acids and vitamins in the gut.[58] In particular, intestines in germ-free animals generally show changed gut morphology, including atypical epithelial structure, less efficient nutrient usage, and intestinal inflammation.[59-61] The antibiotic-induced disruption of the gut bacterial ecology may thus promote an inflammatory disruption of absorptive abilities of intestinal brush border, which could lead to malabsorption of amino acids and SCFAs.[62] Additionally, since > 50% of the fecal mass generally consists of bacteria,[2] it is conceivable that the amino acids extracted from feces might also be derived from the gut bacteria themselves and that the observed reduction in fecal amino acids reflects perturbed amino acids metabolism as well as reduced bacterial population due to vancomycin treatment.

Changes were noted in urinary α-ketoisocaproate and creatine levels following antibiotic treatment. In the human gut, the anaerobic genus *Clostridium* were found to metabolize leucine to isocaproate and α-ketoisocaproate[63]; and creatine has been shown to be co-metabolized in mammals and their gut microbiota.[64,65] Perturbed gut microbial changes observed in SCFAs, oligosaccharides and amino acids indicated vancomycin-induced changes in metabolism of these compounds, which may also

explain the change in the relative amounts of α-ketoisocaproate and creatine in the urine.

This work has shown the potential of a metabolic profiling strategy for studying the effects of antibiotics on the gut microbiota and has provided insights into the metabolic changes associated with antibiotic treatment and its effect on gut microbiota modification. Furthermore, urinary hippurate levels correlated closely with the amino and SCFA profiles in the feces. Our metabolic profiling approach showed changes in host amino acids metabolism and SCFA metabolism as well as in host metabolism of phenolics due to antibiotic treatment. The methods used here were intended to look at general aspects of the gut microbiome and as such are not specific enough to determine which species are being altered and may be responsible for the changes in the host's metabolite profiles. Further studies using such methods as stable isotope probing, metabonomics and high-throughput sequencing of 16S rRNA genes are needed to start to determine the keystone species in the gut, which are responsible for generating the host's metabotype.

Acknowledgments

References

1. Stephen, A. M.; Cummings, J. H. *J. Med. Microbiol.* 1980, *13*, 45-56.

2. Guarner, F.; Malagelada, J-R. *Lancet* 2003, *361*, 512-519.

3. Tannock, G. W. *Int. J. Epidemiol.* 2005, *34*, 13-15.

4. O'Hara, A. M.; Shanahan F. *EMBO Rep.* 2006, *7*, 688-693.

5. Barbara, G.; Stanghellini, V.; Brandi, G.; Cremon, C.; Di Nardo, G.; De Giorgio, R.; Corinaldesi, R. *Am. J. Gastroenterol.* 2005, *100*, 2560-2568.

6. Thompson-Chagoyán, O. C.; Maldonado, J.; Gil, A. *Dig. Dis. Sci.* 2007, online

7. Sokol, H.; Seksik, P.; Rigottier-Gois, L.; Lay, C.; Lepage, P.; Podglajen, I.; Marteau, P.; Dore, J. *Inflammatory Bowel Dis.* 2006, *12*, 106-111.

8. Ley, R. E.; Turnbaugh, P. J.; Klein, S.; Gordon, J. I. *Nature* 2006, *444*, 1023-1024.

9. Turnbaugh, P. J.; Ley, R. E.; Mahowald, M. A.; Magrini, V.; Mardis, E. R.; Gordon, J. I. *Nature* 2006, *444*, 1027-1031.

10. Bäckhed, F.; Manchester, J. K.; Semenkovich, C. F.; Gordon, J. I. *Proc. Natl. Acad. Sci. U. S. A.* 2007, *104*, 979-984.

11. Phipps, A. N.; Stewart, J.; Wright, B.; Wilson, I. D. *Xenobiotica* 1998, *28*, 527-537.

12. Nicholls, A. W.; Mortishire-Smith, R. J.; Nicholson J. K. *Chem. Res. Toxicol.* 2003, *16,* 1395-1404.

13. Williams R. E.; Eyton-Jones H. W.; Farnworth M. J.; R. Gallagher; Provan W. M. *Xenobiotica* 2002, *32*, 783-794.

14. Holmes, E.; Nicholson, J. K. *Toxicol. Sci.* 2005, *37*, 1-2.

15. Robosky, L. C.; Wells, D. F.; Egnash, L. A.; Manning, M. L.; Reily, M. D.; Robertson, D. G. *Toxicol. Sci.* 2005, *87*, 277-284.

16. Dumas, M. E.; Barton, R. H.; Toye, A.; Cloarec, O.; Blancher, C.; Rothwell, A.; Fearnside, J.; Tatoud, R.; Blanc, V.; Lindon, J. C.; Mitchell, S. C.; Holmes, E.; McCarthy, M. I.; Scott, J.; Gauguier, D.; Nicholson, J. K. *Proc. Natl. Acad. Sci. U. S. A.* 2006, *103*, 12511-12516.

17. Martin, F-P.; Dumas, M-E.; Wang, Y.; Legido-Quigley, C.; Yap, I. K. S.; Tang, H.; Zirah, S.; Murphy, G. M.; Cloarec, O.; Lindon, J. C.; Sprenger, N.; Fay, L. B.; Kochhar, S.; van Bladeren, P.; Holmes, E.; Nicholson, J. K. *Mol. Syst. Biol.* 2007, 3:112.

18. Martin, F. P.; Verdu, E. F.; Wang, Y.; Dumas, M. E.; Yap, I. K. S.; Cloarec, O.; Bergonzelli, G. E.; Corthesy-Theulaz, I.; Kochhar, S.; Holmes, E.; Lindon, J. C.; Collins, S. M.; Nicholson, J. K. *J. Proteome Res.* 2006, *5,* 2185-2193.

19. Halligan S, Byard SJ, Spencer AJ, Gray TJ, Harpur ES, Bonner FW. *Toxicol Lett.* 1995, *81,* 15-21.

20. Murgatroyd, L. B.; Pickford, R. J.; Smith, I. K.; Wilson, I. D.; Middleton, B. J. *Human Exp. Toxicol.* 1992, *11*, 35-41.

21. Lenz, E. M; Bright, J; Knight, R; Westwood, F. R; Davies, D; Major, H; Wilson, I. D. *Biomarkers* 2005, *10*, 173-187.

22. Ramo Rao, A. V.; Mukund, K.; Gurjar, K.; Reddy, L, Srinivasa Rao, A. *Chem. Rev.* 1995, *95*, 2135-2167.

23. Pultz, N. J.; Stiefel, U.; Donskey, C. J. *Antimicrob. Agents Chemother.* 2005, *49*, 3513-3516.

24. Nicholson, J. K.; Foxall, P. J.; Spraul, M.; Farrant, R. D.; Lindon, J. C. *Anal. Chem.* 1995, *67*, 793-811.

25. Fan, T. W. M. *Prog. Nucl. Magn. Reson. Spectrosc.* 1996, *28*, 161-219.

26. Cloarec, O.; Dumas, M. E.; Craig, A.; Barton, R. H.; Trygg, J.; Hudson, J.; Blancher, C.; Gauguier, D.; Lindon, J. C.; Holmes, E.; Nicholson, J. K. *Anal. Chem.* 2005, *77*, 1282-1289.

27. Trygg, J. *J. Chemom.* 2002, *16*, 283-293.

28. Cloarec, O.; Dumas, M. E.; Trygg, J.; Craig, A.; Barton, R. H.; Lindon, J. C.; Nicholson, J. K.; Holmes, E. *Anal. Chem.* 2005, *77*, 517-526.

29. Vanhoutte, T.; Huys, G.; De Brandt, E.; Swings, J. *FEMS Microbiol. Ecol.* 2004, 48, 437-446.

30. Scanlan, P. D.; Shanahan, F. Clune, Y.; Collins, J. K.; O'Sullivan, G. C.; O'Riordan, M.; Holmes, E.; Wang, Y.; Marchesi, J. R. *Environ. Microbiol.* 2008, 10, 789-798.

31. Wang, Q.; Garrity, G. M.; Tiedje, J. M.; Cole, J. R. *Appl. Environ. Microbiol.* 2007, 73, 5261-5267.

32. De La Cochetière, M. F.; Durand, T.; Lepage, P.; Bourreille, A.; Galmiche, J. P.; Doré, J. *J. Clin. Microbiol.* 2005, 43, 5588-5592.

33. Wilcox, M. H. *Best Pract. Res. Clin. Gastroenterol.* 2003, 17, 475-493.

34. Li, M.; Wang, B.; Zhang, M.; Rantalainen, M.; Wang, S.; Zhou, H.; Zhang, Y.; Shen, J.; Pang, X.; Zhang, M.; Wei, H.; Chen, Y.; Lu, H.; Zuo, J.; Su, M.; Qiu, Y.; Jia, W.; Xiao, C.; Smith, L. M.; Yang, S.; Holmes, E.; Tang, H.; Zhao, G.; Nicholson, J. K.; Li, L.; Zhao, L. *Proc. Natl. Acad. Sci. U. S. A.* 2008, 105, 2117-2122.

35. Nicholson, J. K. *Mol. Syst. Biol.* 2006, 2:52.

36. Beckwith-Hall, B. M.; Holmes, E.; Lindon, J. C.; Gounarides, J.; Vickers, A.; Shapiro, M.; Nicholson, J. K. *Chem. Res. Toxicol.* 2002, 15, 1136-1141.

37. Goodwin, B. L.; Ruthven, C. R.; Sandler, M. *Biochem. Pharmacol.* 1994, *47*, 2294-2297.

38. Schwab, A. J.; Tao, L.; Yoshimura, T.; Simard, A.; Barker, F.; Pang, K. S. *Am. J. Physiol. Gastrointest. Liver. Physiol.* 2001, *280*, G1124-G1136.

39. Asatoor, A. M. *Biochim. Biophys. Acta.* 1965, 100, 290-292.

40. Diaz, E.; Ferrández, A.; Prieta, M. A.; Garcia, J. *Microbiol. Mol. Biol. Rev.* 2001, *65*, 523-569.

41. Zeisel, S. H.; Da Costa, K.; Fox, J. G. *Biochem. J.* 1985, *232*, 403-408.

42. Smith, J. L.; Wishnok, J. S.; Deen, W. M. *Toxicol. Appl. Pharmacol.* 1994, *125*, 296-308.

43. Salanitro, J. P.; Wegener, W. S. *J. Bacteriol.* 1971, *108*, 885-892.

44. Titgemeyer, E. C.; Bourquin, L. D.; Fahey Jr., G. C.; Garleb, K. A. *Am. J. Clin. Nutr.* 1991, *53*, 1418-24.

45. Topping, D. L.; Clifton, P. M. *Physiol. Rev.* 2001, *81*, 1031-1064.

46. Macfarlane, S.; Macfarlane, G. T. *Proc. Nutr. Soc.* 2007, *62*, 67-72.

47. Bender, A.; Breves, G.; Stein, J.; Leonhard-Marek, S.; Schroder, B.; Winckler, C. *Z. Gastroenterol.* 2001, *11*, 911-918.

48. Walker, A. W.; Duncan, S. H.; McWilliam Leith, E. C.; Child, M. W.; Flint, H. J. *Appl. Environ. Microbiol.* 2005, *71*, 3692-3700.

49. Wong, J. M.; de Souza, R.; Kendall, C. W.; Emam, A.; Jenkins, D. J. *J. Clin. Gastroenterol.* 2006, *40*, 235-243.

50. Oltmer, S.; von Engelhardt, W. *Scand. J. Gastroenterol.* 1994, *29*, 1009-1016.

51. Gonthier, M-P.; Verny, M-A.; Besson, C.; Remesy, C.; Scalbert, A. *J. Nutr.* 2003, *133*, 1853-1859.

52. Coldham, N. G.; Darby, C.; Hows, M.; King, L. J.; Zhang, A. Q.; Sauer, M. J. *Xenobiotica* 2002, *32*, 45-62.

53. Woodmansey, E. J.; McMurdo, M. E.; Macfarlane, G. T.; Macfarlane, S. *Appl. Environ. Microbiol.* 2004, *70*, 6113-6122.

54. Rycroft, C. E.; Jones, M. R.; Gibson, G. R.; Rastall, R. A. *J. Appl. Microbiol.* 2001, 91, 878-887.

55. Zampa, A.; Silvi, S.; Fabiani, R.; Morozzi, G.; Orpianesi, C.; Cresci, A. *Anaerobe* 2004, 10, 19-26.

56. Archer, S.; Meng, S. F.; Wu, J.; Johnson, J.; Tang, R.; Hodin, R. *Surgery* 1998, 124, 248-253.

57. Fuller, M. F.; Tome, D. *J AOAC Int.* 2005, *88*, 923-34.

58. Cummings, J. H.; Macfarlane, G. T. *J. Parenter. Enteral Nutr.* 1997, *21*, 357-365.

59. Cebra, J. J. *Am. J. Clin. Nutr.* 1999, 69, 1046S-1051S.

60. Gordon, J. I.; Hooper, L. V.; McNevin, M. S.; Wong, M.; Bry, L. *Am. J. Physiol.* 1997, 273, G565-570.

61. Shanahan, F. *Best Pract. Res. Clin. Gastroenterol.* 2002, 16, 915-931.

62. Linskens, R. K.; Huijsdens, X. W.; Savelkoul, P. H.; Vandenbroucke-Grauls, C. M.; Meuwissen, S. G. *Scand. J. Gastroenterol.* 2001, *36*, Suppl. 234, 29-40.

63. Kim, J.; Darley, D.; Selmer, T.; Buckel, W. *Appl. Environ. Microbiol.* 2006, *72*, 6062-6069.

64. Wyss, M.; Kaddurah-Daouk, R. *Physiol Rev.* 2000, *80*, 1107-1213.

65. Brosnan, J. T.; Brosnan, M. E. *Annu. Rev. Nutr.* 2007, *27*, 41-261.

Figure Legend:

Figure 1. Typical 600 MHz ^{1}H NMR spectra of urine obtained from untreated mice (A), and vancomycin-treated mice (B) 2 days after the final dosing. (C) PCA trajectory plots of urine. Color code: grey (control), black (vancomycin-treated d-1), red (d1), green (d2), yellow (d3), blue (d5), purple (d7), dark blue (d13 & d19).

Keys: 5, lactate; 7, acetate; 14, succinate; 17, taurine; 18, glycine; 22, α-ketoisocaproate; 23, butyrate; 24, α-ketoisovalerate; 25, N-acetyl glycoproteins (NAG); 26, pyruvate; 27, α-ketoglutarate; 28, dimethylglycine; 29, dimethylamine; 30, trimethylamine; 31, creatine; 32, creatinine; 33, trimethylamine-N-oxide (TMAO); 34, guanidoacetic acid (GAA); 35, hippurate; 36, fumarate; 37, phenylacetylglycine; 38, citrate.

Figure 2. (A) O-PLS-DA scores and coefficient plots derived from the ^{1}H NMR spectra of urine indicating discrimination between untreated and vancomycin-treated mice 2 days after the final dosing. The color code corresponds to the correlation coefficients of the variables. For metabolites identification key, please see Figure 1 caption. (B) Integration of selected peaks from hippurate, creatine and PAG in total area-normalised urinary spectra at all time points, demonstrating the concentrations of metabolites varied as the time progressed. Error bars represent the standard error.

Figure 3. Typical 600 MHz ^{1}H NMR spectra of fecal extracts obtained from untreated mice (A), and vancomycin-treated mice (B) 2 days after the final dosing. (C) PCA trajectory plots of fecal water. Color code: grey (control), black (vancomycin-treated d-1), red (d1), yellow (d3), blue (d5), purple (d7), dark blue (d13 & d19).

Keys: 1, isoleucine; 2, leucine; 3, valine; 4, propionate; 5, lactate; 6, alanine; 7, acetate; 8, glutamate; 9, aspartate; 10, asparagine; 11, methionine; 12, lysine; 13, arginine; 14, succinate; 15, glutamine; 16, choline; 17, taurine; 18, glycine; 19, uracil; 20, tyrosine; 21, phenylalanine; 23, butyrate.

Figure 4. (A) O-PLS-DA scores and coefficient plots derived from the ^{1}H NMR spectra of fecal extract indicating discrimination between untreated and vancomycin-treated mice 2 days after the final dosing. The color code corresponds to the

correlation coefficients of the variables. For metabolite identification key, see Figure 3 caption. (B) Integration of selected peaks from acetate, butyrate and 5-aminovalerate in total area-normalised faecal water spectra for all time points, demonstrating the concentrations of metabolites varied as the time progressed. Error bars represent standard error.

Key: * Vancomycin vehicle peak did not contribute to the separation of the 2 classes of animal and was therefore removed from the analysis (inset).

Figure 5. O-PLS regression of (A) urinary hippurate and (B) urinary phenylacetylglycine against the fecal extract ^{1}H NMR spectra profiles.

Figure 1

Figure 2

Figure 3

A

B

C

Figure 4

Figure 5

Table 1. Metabolic effects of vancomycin treatment on feces of mice

Metabolites	Chemical shift	Untreated vs. vancomycin-treated (correlation coefficient) Faeces $Q^2 = 0.92$ $R^2 = 0.98$
acetate	1.92 (s)	+0.88
alanine	1.48 (d)	+0.97
arginine	1.63 (m)	+0.96
asparagine	2.94 (m)	+0.82
aspartate	2.79 (m)	+0.90
n-butyrate	0.90 (t)	+0.86
choline	3.23 (s)	-0.69 [a]
glutamate	2.08 (m)	+0.91
glycine	3.56 (s)	+0.65 [a]
isoleucine	1.02 (d)	+0.95
lactate	1.32 (d)	+0.48[a]
leucine	0.96 (t)	+0.94
lysine	1.72 (m)	+0.95
methionine	2.13 (s)	+0.93
oligosaccharides	3.5 - 4.0	-0.90
phenylalanine	7.40 (t)	+0.95
propionate	2.19 (q)	+0.90
taurine	3.46 (t)	+0.81
tyrosine	6.87 (dd)	+0.89
uracil	5.81 (d)	+0.91
valine	1.04 (d)	+0.94

Key: [a] Shows trend but not significant at the level of $P<0.05$

Table 2. Metabolic effects of vancomycin treatment on urine of mice

Metabolites	Chemical shift	Untreated vs. vancomycin-treated (correlation coefficient) Urine $Q^2 = 0.75$ $R^2 = 0.98$
α-ketoisovalerate	1.13 (d)	-0.64 [a]
n-butyrate	0.90 (t)	-0.58 [a]
creatine	3.93 (s)	-0.60 [a]
creatinine	4.06 (s)	-0.45[a]
GAA	3.80 (s)	-0.75
glycine	3.56 (s)	-0.47[a]
hippurate	7.84 (d)	+0.86
NAG	2.06 (s)	-0.64 [a]
phenylacetylglycine	7.43 (m)	+0.67 [a]
taurine	3.46 (t)	+0.49[a]
TMA	2.89 (s)	+0.55 [a]
TMAO	3.27 (s)	+0.50 [a]

Key: [a] Shows trend but not significant at the level of P<0.05; GAA, guanidoacetic acid; NAG, *N*-acetyl glycoproteins; TMA, trimethylamine; TMAO, trimethyl-*N*-oxide

Table 3. O-PLS model summary of the correlations between urinary hippurate and phenylacetylglycine with fecal metabolites for day 1 (D_1), day 3 (D_3), day 7 (D_7), day 13 (D_{13}) and day 19 (D_{19})

Time point	hippurate			PAG		
	Q^2	R^2	Number of components	Q^2	R^2	Number of components
D_1	71%	57%	1	<0	-	-
D_3	56%	64%	3	37%	60%	2
D_7	63%	64%	5	13%	20%	1
D_{13}	52%	38%	3	<0	-	-
D_{19}	17%	22%	1	<0	-	-

Table 4. Taxonomic affiliation of the partial 16S rRNA gene sequence obtained from the excised DGGE band. The rows shaded in grey are the closest hits to bacteria, which have been cultured

Phyla	Class	Order	Family	Genus	Species	Accesion number	Similarity (%)
Firmicutes	*Mollicutes*	*Anaeroplasmatales*	*Anaeroplasmataceae*	*Anaeroplasma*	Uncultured bacterium	AY960576	92
Firmicutes	*Mollicutes*	*Anaeroplasmatales*	*Anaeroplasmataceae*	*Anaeroplasma*	*Anaeroplasma bactoclasticum*	M25049	90
Firmicutes	*Mollicutes*	*Anaeroplasmatales*	*Anaeroplasmataceae*	*Anaeroplasma*	Uncultured bacterium	EU006469	92
Firmicutes	*Clostridia*	*Clostridiales*	*Eubacteriaceae*	*Eubacterium*	*Eubacterium desmolans*	L34618	83
Firmicutes	*Clostridia*	*Clostridiales*	*Clostridiaceae*	*Clostridium*	Uncultured bacterium	EF406679	97
Firmicutes	*Clostridia*	*Clostridiales*	*Clostridiaceae*	*Clostridium*	*Clostridium cocleatum*	AF028350	97
Firmicutes	*Clostridia*	*Clostridiales*	*Clostridiaceae*	*Clostridium*	Uncultured bacterium	EF603657	97
Firmicutes	*Clostridia*	*Clostridiales*	*Clostridiaceae*	*Clostridium*	*Clostridium sp. BA-1*	AB196728	83
Firmicutes	*Clostridia*	*Clostridiales*	*Lachnospiraceae*	*Incertae sedis*	Uncultured bacterium	EF704431	96
Firmicutes	*Clostridia*	*Clostridiales*	*Clostridiaceae*	*Clostridium*	*Clostridium symbiosum*	EF442669	95
Firmicutes	*Clostridia*	*Clostridiales*	*Clostridiaceae*	*Ruminococcus*	Uncultured bacterium	AY976513	58
Firmicutes	*Clostridia*	*Clostridiales*	*Lachnospiraceae*	*Anaerostipes*	butyrate-producing bacterium SS2/1	AY305319	60
Proteobacteria	*Gammaproteobacteria*	*Enterobacteriales*	*Enterobacteriaceae*	*Escherichia*	Uncultured bacterium	EF674507	94
Proteobacteria	*Gammaproteobacteria*	*Enterobacteriales*	*Enterobacteriaceae*	*Photorhabdus*	*Photorhabdus luminescens*	DQ518589	93

Synopsis

Metabolic profiling of antibiotic model illustrates the close inter-relationship between the host and microbial "metabotypes", and provides a basis for further experiments to probe and understand the complex microbial-mammalian metabolic axis. This work has shown the potential of metabolic profiling tools, coupled with microbiological analysis, for studying the effects of antibiotics on the gut microbiota and has provided insights into the metabolic changes associated with antibiotic treatment and its effect on gut microbiota modification.